Market closed
Bicara Therapeutics/$BCAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bicara Therapeutics
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
Ticker
$BCAX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
55
ISIN
US0554771032
Website
BCAX Metrics
BasicAdvanced
$747M
-
-$3.05
-
-
Price and volume
Market cap
$747M
52-week high
$28.09
52-week low
$8.91
Average daily volume
576K
Financial strength
Current ratio
24.621
Quick ratio
24.167
Total debt to equity
0.129
Management effectiveness
Return on equity (TTM)
-27.26%
Valuation
Price to book
1.63
Price to tangible book (TTM)
1.63
Price to free cash flow (TTM)
-4.692
Growth
Earnings per share change (TTM)
-96.69%
BCAX News
AllArticlesVideos
Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·3 days ago
Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025
GlobeNewsWire·3 weeks ago
Bicara: Innovative Precision Tumor Targeting
Seeking Alpha·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Bicara Therapeutics stock?
Bicara Therapeutics (BCAX) has a market cap of $747M as of May 16, 2025.
What is the P/E ratio for Bicara Therapeutics stock?
The price to earnings (P/E) ratio for Bicara Therapeutics (BCAX) stock is 0 as of May 16, 2025.
Does Bicara Therapeutics stock pay dividends?
No, Bicara Therapeutics (BCAX) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Bicara Therapeutics dividend payment date?
Bicara Therapeutics (BCAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Bicara Therapeutics?
Bicara Therapeutics (BCAX) does not currently have a Beta indicator.